Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C Jr, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW.

J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27.

2.

Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.

Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, Zhao Y, Kim D, Babich JW.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1841-1851. doi: 10.1007/s00259-018-4004-5. Epub 2018 Apr 6.

PMID:
29623376
3.

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M.

J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.

4.

Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.

Umbricht CA, Benešová M, Schibli R, Müller C.

Mol Pharm. 2018 Jun 4;15(6):2297-2306. doi: 10.1021/acs.molpharmaceut.8b00152. Epub 2018 May 2.

PMID:
29684274
5.

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.

Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG.

J Nucl Med. 2016 Oct;57(10):1569-1575. Epub 2016 May 26.

6.

Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.

Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, DiMagno SG, Babich JW.

J Nucl Med. 2019 May;60(5):656-663. doi: 10.2967/jnumed.118.221150. Epub 2018 Dec 14.

PMID:
30552199
7.

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.

8.

Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.

Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.

Mol Pharm. 2018 Nov 5;15(11):5183-5191. doi: 10.1021/acs.molpharmaceut.8b00720. Epub 2018 Oct 5.

PMID:
30251544
9.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

J Nucl Med. 2013 Aug;54(8):1369-76. doi: 10.2967/jnumed.112.116624. Epub 2013 Jun 3.

10.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

11.

Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.

Benešová M, Umbricht CA, Schibli R, Müller C.

Mol Pharm. 2018 Mar 5;15(3):934-946. doi: 10.1021/acs.molpharmaceut.7b00877. Epub 2018 Feb 5.

PMID:
29400475
12.

Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.

Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H.

J Nucl Med. 2016 Dec;57(12):1978-1984. Epub 2016 Jul 14.

13.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.

J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.

14.

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.

Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Ponnala S, Babich JW.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15.

15.

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.

Wüstemann T, Bauder-Wüst U, Schäfer M, Eder M, Benesova M, Leotta K, Kratochwil C, Haberkorn U, Kopka K, Mier W.

Theranostics. 2016 Apr 28;6(8):1085-95. doi: 10.7150/thno.13448. eCollection 2016.

16.

A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.

Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H.

Mol Imaging Biol. 2017 Dec;19(6):915-922. doi: 10.1007/s11307-017-1121-7.

PMID:
28924629
17.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.

Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.

J Nucl Med. 2014 Nov;55(11):1791-8. doi: 10.2967/jnumed.114.140426. Epub 2014 Oct 23.

18.

Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, Pomper MG.

Bioconjug Chem. 2016 Jun 15;27(6):1447-55. doi: 10.1021/acs.bioconjchem.5b00679. Epub 2016 May 9.

19.

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.

20.

Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.

Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K.

J Nucl Med. 2017 Mar;58(3):425-431. doi: 10.2967/jnumed.116.181768. Epub 2016 Oct 27.

Supplemental Content

Support Center